GRAPHCMS
24.11.2021 18:02:09 CET | Business Wire | Press release
GraphCMS — the Berlin-based company behind the headless GraphQL content federation platform that helps leading companies unify the content layer by federating business-critical APIs — announced today that they have joined the MACH alliance , an independent group of tech companies advocating for an open and best-of-breed enterprise technology ecosystem. As part of the MACH alliance, GraphCMS will work closely with the other members to guide companies on how they can benefit from a lean and modular approach to enterprise technologies, by adopting MACH (microservices, API-first, Cloud-native SaaS, and Headless) architectures.
Liberating data effectively from legacy and third-party systems is a key challenge for digitally-driven enterprises as they strive towards creating immersive, high-performance digital experiences. GraphCMS’s leading content management capabilities and novel approach to remote data fetching from external systems such as other MACH vendors — dubbed “Content Federation ” — enables microservices to talk to each other, helping organizations deliver cutting-edge digital experiences across platforms, from streaming services to innovative new eCommerce platforms in a fraction of the time. Companies can build complex applications while aggregating their data from multiple sources into a single API, effectively eliminating content silos and “API Sprawl”.
“The MACH alliance’s ethos of encouraging companies in adopting modern, composable microservices rather than monolithic suites is extremely aligned with our own vision at GraphCMS, as we work with our customers in modernizing their stacks using best-of-breed solutions ”, explains Christopher Kühn , CCO at GraphCMS.
Already supporting companies like Telenor , Burrow , 2U Inc. , and Prym in their ambitious initiatives to deliver better digital experiences to millions of consumers via Content Federation, GraphCMS aims to accelerate the enterprise adoption of MACH compliant software architectures as the “glue” that federates them together into a single GraphQL API.
“We’re thrilled to be joining the MACH Alliance. Their approach represents the future of software, where companies are in charge of defining composable tech stacks that are perfectly aligned with scaling their business model, rather than adapting to inflexible monolithic suites ”, adds Ronak Ganatra, VP of Marketing at GraphCMS.
About GraphCMS
GraphCMS is the first enterprise-class headless content management and federation platform that enables data unification from multiple APIs. With the industry's most versatile GraphQL content APIs and a novel approach in external data sourcing via API extensions, the content platform enables use cases beyond simple headless CMS' capabilities. Enterprise customers see GraphCMS as a database highly optimized for structured content while giving content creators the tools to build their ultimate content pipeline. GraphCMS is developed by GraphCMS GmbH, headquartered in Berlin, Germany, and is currently enabling over 50,000 teams across the world to rapidly build and deliver tomorrow’s omnichannel digital experiences at scale.
About the MACH Alliance
The MACH Alliance is a [501(c)(6)] non-profit organization, governed by an independent board and does not endorse specific vendors, members, or otherwise. The Alliance was formed in June 2020 to help enterprise organizations navigate the complex modern technology landscape. It aims to guide and show the business advantage of open tech ecosystems that are Microservices based, API-first, Cloud-native, and Headless. All MACH Alliance members meet certification principles that are published on the website.
Founding members include Amplience, commercetools, Contentstack, EPAM Systems, and Valtech. The MACH Alliance welcomes technology companies and individual industry experts who share the same vision for the future. Learn more at machalliance.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom